Abstract
Influenza-A-viruses have a wide host range and occur with a wide spectrum of variants defined by 16 HA and 9 NA subtypes. All of these subtypes occur in birds, whereas only some of them have so far been observed in man, pig, horse, and a number of other mammals. In contrast, influenza-B and C-viruses occur only in man, and there are no subtypes of these viruses. Influenza-A-viruses occasionally can be transmitted from aquatic birds, their natural reservoir, to terrestrial birds and mammals. On rare occasions, they adapt to the new species and establish thus new virus lineages. Adaptation requires multiple mutations and it may involve gene reassortment after co-infection with another virus. By these mechanisms, viruses with new surface glycoproteins and therefore a distinct change in antigenicity are generated. If a new virus with such an antigenic shift occurs in man, it causes a pandemic. Antigenic drift, unlike antigenic shift, is characterized by slight changes in antigenicity resulting from successive mutations in HA and NA. Antigenic drift is responsible for the annual human epidemics. It occurs not only with influenza-A-viruses, but also with influenza-B viruses.
Influenza is a highly contagious disease that is transmitted by aerosols. Virus replication occurs in airway epithelia and reaches its peak 2–3 days after infection. Symptoms typically include high fever, chills, headache, sore throat, dry cough, myalgias, anorexia, and malaise. Complications include primary viral pneumonia, secondary bacterial pneumonia, or combined bacterial and viral pneumonia. Serious complications of influenza most often occur in people 65 years of age and older, in the very young, and in those of any age with underlying chronic cardiac, pulmonary, or metabolic disease. Vaccination is the most potent instrument for influenza control. Prime candidates for vaccination are persons at risk for complications and individuals who might transmit influenza to such persons. Inactivated vaccines obtained from infected chicken embryos are most commonly used. Neuraminidase inhibitors are the influenza antivirals of choice. Application is limited to a relatively small time window shortly before or after infection.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Cox NJ, Neumann G, Donis RO, Kawaoka Y (2005) Orthomyxoviruses: influenza. In: BWJ Mahy, V ter Meulen (eds): Topley and Wilson’s microbiology and microbial infections, Virology, Vol. 1. Hodder Arnold, London, 634–698
Noah DL, Krug RM (2005) Influenza virus virulence and its molecular determinants. Adv Virus Res 65: 121–145
Klenk H-D, Garten W (1994) Host cell proteases controlling virus pathogenicity. Trends Microbiol 2: 39–43
Nicholson KG (1998) Human influenza. In: KG Nicholson, RG Webster, AJ Hay (eds): Textbook of influenza. Blackwell Science, Oxford, 219–264
Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk H-D (2004) Human and avian influenza viruses target different cell types in cultures of human airway epithelium. Proc Natl Acad Sci USA 101: 4620–4624
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2007 Birkhäuser Verlag Basel/Switzerland
About this chapter
Cite this chapter
Klenk, HD. (2007). Influenza. In: Community-Acquired Pneumonia. Birkhäuser Advances in Infectious Diseases. Birkhäuser Basel. https://doi.org/10.1007/978-3-7643-7563-8_5
Download citation
DOI: https://doi.org/10.1007/978-3-7643-7563-8_5
Publisher Name: Birkhäuser Basel
Print ISBN: 978-3-7643-7562-1
Online ISBN: 978-3-7643-7563-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)